FDA calendar · March 2022 · built from SEC filings

PDUFA dates March 2022: FDA calendar and catalysts.

Updated Snapshot 20261116T112050ZBuilt

0 PDUFA dates fell in March 2022. The FDA calendar also recorded 27 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in March 2022

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

March 2022: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
Mar 2022Month disclosedVafseo® (vadadustat)AKBANDA/BLA submission—CompletedSEC Form 10-Q
March 1, 2022Mayzent (siponimod)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
Mar 2022Month disclosedMVASI® (bevacizumab)OTLKNDA/BLA submissionwet AMDCompletedSEC Form 10-Q
March 4, 2022Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
March 4, 2022DARZALEX (daratumumab)JNJLabel expansion—ApprovedopenFDA Drugs@FDA
March 11, 2022LYNPARZA® (olaparib)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
March 15, 2022Atropine Sulfate (atropine sulfate)BLCOFDA approval—ApprovedopenFDA Drugs@FDA
March 16, 2022RINVOQ® (upadacitinib)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
March 18, 2022Opdualag (nivolumab; relatlimab-rmbw)BMYFDA approvalTo treat unresectable or metastatic melanomaApprovedFDA Novel Drug Approvals
March 21, 2022KEYTRUDA® (pembrolizumab)MRKLabel expansion—ApprovedopenFDA Drugs@FDA
March 22, 2022Empliciti (elotuzumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
March 23, 2022Vocabria (cabotegravir sodium)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
March 23, 2022Cabenuva Kit (cabotegravir; rilpivirine)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
March 23, 2022Gozellix (gallium ga-68 gozetotide)NVSFDA approval—ApprovedopenFDA Drugs@FDA
March 23, 2022Pluvicto (lutetium lu-177 vipivotide tetraxetan)NVSFDA approval—ApprovedFDA Novel Drug Approvals
March 28, 2022Wegovy (semaglutide)NVOLabel expansion—ApprovedopenFDA Drugs@FDA
March 29, 2022Vafseo® (vadadustat)AKBAComplete Response Letteranemia associated with chronic kidney disease, or CKDCRL issuedSEC Form 10-Q
March 29, 2022Edurant Ped (rilpivirine hydrochloride)JNJLabel expansion—ApprovedopenFDA Drugs@FDA
March 30, 2022Triumeq Pd (abacavir sulfate; dolutegravir sodium; lamivudine)GSKFDA approval—ApprovedopenFDA Drugs@FDA
March 30, 2022Triumeq Pd (abacavir sulfate; dolutegravir sodium; lamivudine)GSKLabel expansion—ApprovedopenFDA Drugs@FDA

March 2022: dated readouts

DateDrugCompanyEventIndicationStatusSource
Mar 2022Month disclosedTransConASNDTopline readout—Met primary endpointSEC Form 8-K
Mar 2022Month disclosed—IRDTopline readout—Positivesec_424b
March 22, 2022VYVGART (efgartigimod)ARGXTopline readoutgMGMet primary endpointSEC 8-K Exhibit 99.1

March 2022: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Mar 2022Month disclosedobicetrapibNAMSTrial start—CompletedSEC 8-K Exhibit 99.1
Mar 2022Month disclosedcisplatin (DMS32212R)AIMTrial start—CompletedSEC Form 10-Q
Mar 2022Month disclosedlatozinemab (AL001)ALZNTrial start—CompletedSEC Form 10-K
Mar 2022Month disclosedNUV-868NUVBTrial startadvanced solid tumors to determine a maximum tolerated doseCompletedSEC Form 10-K

Questions

What PDUFA dates are in March 2022?

0 PDUFA dates fell in March 2022. The FDA calendar also recorded 27 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.